What is DeepLife?
DeepLife operates at the intersection of systems engineering and molecular biology, addressing the fundamental challenge of cellular pathology. By leveraging state-of-the-art machine learning algorithms to analyze complex multi-omics data, the company identifies the specific molecular triggers that drive cells into pathological states. This analytical framework allows DeepLife to simulate and reverse disease-causing mechanisms, effectively engineering pathways to restore cellular health. As a leader in the emerging TechBio landscape, the firm provides a sophisticated alternative to traditional, iterative biological research, offering a high-precision approach to drug discovery and therapeutic development.
How much funding has DeepLife raised?
DeepLife has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Groupe Prunay, Beiersdorf, YZR Capital, and Relyens en France
Key Investors in DeepLife
YZR Capital
A Munich-based venture capital firm specializing in early-stage HealthTech, providing strategic guidance and capital to companies innovating in AI-powered diagnostics and TechBio.
Beiersdorf
A global leader in skincare manufacturing, known for brands like NIVEA and Eucerin, with a strategic interest in scientific innovation and advanced biological research.
Groupe Prunay
A diversified family-owned group that manages venture capital investments alongside its core operations in insurance and real estate, focusing on high-growth potential businesses.
What's next for DeepLife?
With this major enterprise-level funding, DeepLife is poised to scale its operational capacity and expand its footprint within the global healthcare innovation ecosystem. The strategic focus will likely shift toward validating its computational models in clinical settings and forging deeper partnerships with pharmaceutical entities seeking to optimize their R&D pipelines. By integrating its systems engineering expertise with broader clinical data, DeepLife aims to establish a new standard for predictive medicine, ultimately reducing the time and cost associated with identifying effective therapeutic interventions for complex diseases.
See full DeepLife company page
